Oral Semaglutide Demonstrates Significant Weight Loss Efficacy in East Asian Adults with Overweight or Obesity: Insights from the OASIS 2 Trial
Highlight
– Oral semaglutide 50 mg once daily led to a robust 14.3% mean body weight reduction in East Asian adults with overweight or obesity over 68 weeks.
– The therapy demonstrated significant efficacy both in participants with and without type 2 diabetes (T2D).
– 84.3% of semaglutide-treated participants achieved clinically meaningful weight loss of 5% or more versus 17.2% with placebo.
– Gastrointestinal adverse events were common but generally manageable; treatment discontinuation due to adverse events was low (4.5%).
Study Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.